ATE509622T1 - Amphetamin-ornithine konjugate sowie herstellungs-und verwendungsverfahren - Google Patents
Amphetamin-ornithine konjugate sowie herstellungs-und verwendungsverfahrenInfo
- Publication number
- ATE509622T1 ATE509622T1 AT07869098T AT07869098T ATE509622T1 AT E509622 T1 ATE509622 T1 AT E509622T1 AT 07869098 T AT07869098 T AT 07869098T AT 07869098 T AT07869098 T AT 07869098T AT E509622 T1 ATE509622 T1 AT E509622T1
- Authority
- AT
- Austria
- Prior art keywords
- amphetamine
- conjugates
- ornithine
- disclosed
- production
- Prior art date
Links
- 229960003104 ornithine Drugs 0.000 title 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 229940025084 amphetamine Drugs 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86937506P | 2006-12-11 | 2006-12-11 | |
| PCT/US2007/087028 WO2008073918A1 (en) | 2006-12-11 | 2007-12-10 | Non-standard amino acid conjugates of amphetamine and processes for making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE509622T1 true ATE509622T1 (de) | 2011-06-15 |
Family
ID=39512105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07869098T ATE509622T1 (de) | 2006-12-11 | 2007-12-10 | Amphetamin-ornithine konjugate sowie herstellungs-und verwendungsverfahren |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US7776917B2 (enExample) |
| EP (1) | EP2101571B1 (enExample) |
| JP (1) | JP2010512413A (enExample) |
| CN (1) | CN101594778A (enExample) |
| AT (1) | ATE509622T1 (enExample) |
| AU (1) | AU2007333105A1 (enExample) |
| BR (1) | BRPI0720105A2 (enExample) |
| CA (1) | CA2672138A1 (enExample) |
| ES (1) | ES2364865T3 (enExample) |
| IL (1) | IL198930A0 (enExample) |
| WO (1) | WO2008073918A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060014697A1 (en) * | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
| ATE536867T1 (de) | 2006-03-16 | 2011-12-15 | Tris Pharma Inc | Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen |
| CN101594778A (zh) * | 2006-12-11 | 2009-12-02 | 凯姆制药公司 | 苯丙胺的非标准氨基酸结合物及其制备和使用的方法 |
| EP2109465B1 (en) * | 2007-02-08 | 2012-04-11 | Kempharm, Inc. | Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same |
| DE102007037478B3 (de) | 2007-08-08 | 2008-04-30 | Leifheit Ag | Wäschetrockenständer |
| US8614346B2 (en) | 2009-06-19 | 2013-12-24 | Cambrex Charles City, Inc. | Methods and compositions for preparation of amphetamine conjugates and salts thereof |
| WO2011133348A1 (en) | 2010-04-21 | 2011-10-27 | Pharmacofore, Inc. | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof |
| US8779191B2 (en) | 2010-12-20 | 2014-07-15 | Cambrex Charles City, Inc. | Methods and compositions for preparing lisdexamfetamine and salts thereof |
| CA3123900A1 (en) | 2011-07-28 | 2013-01-31 | Kempharm Inc. | Methylphenidate-prodrugs, processes of making and using the same |
| WO2013019187A1 (en) * | 2011-07-29 | 2013-02-07 | Kempharm, Inc. | Homoarginine prodrugs and/or conjugates of amphetamine and other stimulants and processes for making and using the same |
| SG10201610869TA (en) | 2012-06-26 | 2017-02-27 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti |
| US20140073589A1 (en) * | 2012-06-27 | 2014-03-13 | Shire Ag | Amphetamine Prodrugs |
| EP2906208B1 (en) * | 2012-10-09 | 2019-01-30 | Sears, Douglas | Therapeutic treatment |
| GB2545368B (en) | 2014-10-20 | 2021-04-21 | Elysium Therapeutics Inc | Diversion-resistant opioid formulations |
| US20170056352A1 (en) | 2015-08-25 | 2017-03-02 | Rgenix, Inc. | PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF |
| US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
| GB2556817B (en) | 2015-10-01 | 2019-11-06 | Elysium Therapeutics Inc | Polysubunit opioid prodrugs resistant to overdose and abuse |
| US10335406B2 (en) | 2015-10-01 | 2019-07-02 | Elysium Therapeutics, Inc. | Opioid compositions resistant to overdose and abuse |
| WO2018091473A1 (en) | 2016-11-15 | 2018-05-24 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| WO2018107132A1 (en) | 2016-12-11 | 2018-06-14 | Kempharm, Inc. | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
| WO2018160178A1 (en) | 2017-03-01 | 2018-09-07 | Rgenix, Inc. | Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof |
| AU2018234911B2 (en) | 2017-03-17 | 2024-04-18 | Elysium Therapeutics, Inc. | Polysubunit opioid prodrugs resistant to overdose and abuse |
| CN111107878A (zh) * | 2017-04-10 | 2020-05-05 | 夏尔制药公司 | 使用苯丙胺前药的治疗方法 |
| GB201709141D0 (en) | 2017-06-08 | 2017-07-26 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| US12458592B1 (en) | 2017-09-24 | 2025-11-04 | Tris Pharma, Inc. | Extended release amphetamine tablets |
| US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
| CA3078418A1 (en) * | 2017-10-06 | 2019-04-25 | Instituto De Medicina Molecular Joao Lobo Antunes | Treatment of obesity-related conditions |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| WO2019199731A1 (en) * | 2018-04-10 | 2019-10-17 | Shire Pharmaceuticals Inc. | Amphetamine prodrug and crystalline froms thereof |
| GB201808462D0 (en) | 2018-05-23 | 2018-07-11 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| WO2020181000A1 (en) * | 2019-03-06 | 2020-09-10 | Ensysce Biosciences, Inc. | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof |
| JP2022529781A (ja) | 2019-04-17 | 2022-06-24 | コンパス パスファインダー リミテッド | サイロシビンによるうつ病及び他の様々な障害の治療 |
| JP2023505687A (ja) | 2019-12-11 | 2023-02-10 | インスピルナ，インコーポレーテッド | 癌の処置方法 |
| MX2023010506A (es) | 2021-03-09 | 2023-09-20 | Ensysce Biosciences Inc | Composiciones que comprenden profarmacos de escision enzimatica y nafamostat de liberacion controlada y metodos de uso de estos. |
| TW202309004A (zh) * | 2021-08-24 | 2023-03-01 | 美商精神醫學公司 | 藉由使用受控和非受控中間體獲取ｍｄｍａ前驅藥之合成途徑 |
| CA3230025A1 (en) | 2021-09-29 | 2023-04-06 | Lynn Kirkpatrick | Enzyme-cleavable methadone prodrugs and methods of use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE539185A (enExample) * | 1954-06-28 | |||
| US2881113A (en) * | 1957-01-29 | 1959-04-07 | Ortho Pharma Corp | Therapeutically active compositions containing amphetamines |
| US2892753A (en) * | 1957-02-26 | 1959-06-30 | Boehringer Sohn Ingelheim | Central nervous system stimulant |
| DE1493824A1 (de) | 1964-01-27 | 1969-05-22 | Hoffmann La Roche | Verfahren zur Herstellung von Aminocarbonsaeureamiden |
| DK1685839T3 (da) | 1997-12-22 | 2013-06-24 | Euro Celtique Sa | Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist |
| AU6528400A (en) | 1999-08-23 | 2001-03-19 | David M. Ockert | Triple drug therapy for the treatment of narcotic and alcohol withdrawal symptoms |
| EP1292307A2 (en) | 2000-06-09 | 2003-03-19 | The Regents of The University of California | Method of treating pain using nalbuphine and opioid antagonists |
| US6417184B1 (en) | 2000-09-19 | 2002-07-09 | David M. Ockert | Triple drug therapy for the treatment and prevention of acute or chronic pain |
| US7105486B2 (en) * | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
| AU2003219863C1 (en) | 2002-02-22 | 2009-03-05 | Shire Llc | Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances |
| EP1613261A4 (en) | 2003-04-09 | 2011-01-26 | Novo Nordisk As | INTRA-CELLULAR FORMATION OF PEPTIDE CONJUGATES |
| KR101159477B1 (ko) * | 2003-05-29 | 2012-07-02 | 샤이어 엘엘씨 | 남용 방지성 암페타민 화합물 |
| EP1931357A2 (en) | 2005-09-13 | 2008-06-18 | Shire LLC | Prodrugs of phentermine |
| CN101594778A (zh) | 2006-12-11 | 2009-12-02 | 凯姆制药公司 | 苯丙胺的非标准氨基酸结合物及其制备和使用的方法 |
| EP2109465B1 (en) | 2007-02-08 | 2012-04-11 | Kempharm, Inc. | Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same |
-
2007
- 2007-12-10 CN CNA2007800458802A patent/CN101594778A/zh active Pending
- 2007-12-10 WO PCT/US2007/087028 patent/WO2008073918A1/en not_active Ceased
- 2007-12-10 EP EP07869098A patent/EP2101571B1/en not_active Not-in-force
- 2007-12-10 CA CA002672138A patent/CA2672138A1/en not_active Abandoned
- 2007-12-10 JP JP2009541507A patent/JP2010512413A/ja not_active Withdrawn
- 2007-12-10 US US11/953,668 patent/US7776917B2/en active Active
- 2007-12-10 AU AU2007333105A patent/AU2007333105A1/en not_active Abandoned
- 2007-12-10 ES ES07869098T patent/ES2364865T3/es active Active
- 2007-12-10 AT AT07869098T patent/ATE509622T1/de not_active IP Right Cessation
- 2007-12-10 BR BRPI0720105-2A2A patent/BRPI0720105A2/pt not_active IP Right Cessation
-
2009
- 2009-05-25 IL IL198930A patent/IL198930A0/en unknown
- 2009-05-28 US US12/473,903 patent/US20090234018A1/en not_active Abandoned
-
2010
- 2010-07-26 US US12/843,169 patent/US8101661B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20100292336A1 (en) | 2010-11-18 |
| HK1131518A1 (en) | 2010-01-29 |
| US8101661B2 (en) | 2012-01-24 |
| IL198930A0 (en) | 2010-02-17 |
| CN101594778A (zh) | 2009-12-02 |
| CA2672138A1 (en) | 2008-06-19 |
| JP2010512413A (ja) | 2010-04-22 |
| WO2008073918A1 (en) | 2008-06-19 |
| EP2101571A4 (en) | 2010-01-13 |
| US7776917B2 (en) | 2010-08-17 |
| BRPI0720105A2 (pt) | 2014-10-07 |
| EP2101571A1 (en) | 2009-09-23 |
| AU2007333105A1 (en) | 2008-06-19 |
| ES2364865T3 (es) | 2011-09-15 |
| US20090234018A1 (en) | 2009-09-17 |
| US20080139653A1 (en) | 2008-06-12 |
| EP2101571B1 (en) | 2011-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL198930A0 (en) | Non-standard amino acid conjugates of amphetamine and processes for making and using the same | |
| ATE552861T1 (de) | Polare hydrophile prodrugs von amphetamin und anderen stimulantien sowie herstellungs- und verwendungsverfahren | |
| WO2007015017A3 (fr) | Nouveaux derives de polyquinoleines et leur utilisation therapeutique | |
| WO2007093627A3 (de) | Biozide zusammensetzung | |
| DE602006012665D1 (de) | Kristalline formen von 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-ä4-((r)-tetrahydrofuran-3-yloxy)-benzylü-benzol, zubereitungsverfahren dafür und dessen verwendung zur arzneimittelherstellung | |
| EA201001639A1 (ru) | Композиции и способы их получения и применения | |
| WO2006072393A3 (de) | Sulfonylpyrrolidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| CY1112495T1 (el) | Κυτταροτοξικοι παραγοντες που περιλαμβανουν νεα παραγωγα τομαϋμυκινης | |
| WO2010069532A8 (en) | Antibodies against human angiopoietin 2 | |
| EA200700096A1 (ru) | Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии | |
| WO2006119498A3 (en) | Pharmaceutical compositions with synchronized solubilizer release | |
| DE602007011902D1 (de) | Spiroindolinon-derivate | |
| WO2008046581A3 (de) | Substituierte tetrahydropyrrolopyrazin-verbindungen als inhibitoren der monoaminwiederaufnahme und deren verwendung in arzeimitteln | |
| WO2006136357A3 (de) | Kristalline modifikationen des pyraclostrobins | |
| TW200621313A (en) | Pharmaceutical compositions | |
| EA200900090A1 (ru) | Бензиламины, способ их получения и их применение в качестве противовоспалительных средств | |
| UA94603C2 (ru) | Производные тетрагидронафталина, способ их получения и их применения в качестве ингибиторов воспаления | |
| EA201000039A1 (ru) | Фармацевтическая композиция, включающая солифенацин или его фармацевтически приемлемую соль | |
| WO2007133184A3 (en) | Polypeptides and biosynthetic pathways for the production of stereoisomers of monatin and their precursors | |
| WO2008073863A3 (en) | Preparation and utility of substituted allylamines | |
| MX2009008249A (es) | Composicion farmaceutica que comprende derivado de camptotecina. | |
| DE502006005053D1 (de) | Spritzbare akustikmassen | |
| WO2008107471A3 (en) | Modified hydroxypolymer conjugates with killing effect on tumor cells | |
| MX2009006479A (es) | Derivados de hemicelulosa y estructuras que los emplean. | |
| WO2008023003A8 (de) | Arzneimittelkombinationen zur behandlung von atemwegserkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |